Levi, L. I. & Vignuzzi, M. Arthritogenic Alphaviruses: A Worldwide Emerging Threat? Microorganisms 7, 133 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Organization, W. H. Chikungunya Fact Sheet, (2021).

PAHO. (World Health Organization, Pan American Health Organization, 2015).

Chikungunya Cases by Country or Territory. (2023).

Shocket, M. S., Ryan, S. J. & Mordecai, E. A. Temperature explains broad patterns of Ross River virus transmission. Elife 7, e37762 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Murphy, A. K. et al. Spatial and temporal patterns of Ross River virus in south east Queensland, Australia: identification of hot spots at the rural-urban interface. BMC Infect. Dis. 20, 722 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Serra, O. P., Cardoso, B. F., Ribeiro, A. L., Santos, F. A. & Slhessarenko, R. D. Mayaro virus and dengue virus 1 and 4 natural infection in culicids from Cuiaba, state of Mato Grosso, Brazil. Mem. Inst. Oswaldo Cruz 111, 20–29 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vieira, C. J. et al. Detection of Mayaro virus infections during a dengue outbreak in Mato Grosso, Brazil. Acta Trop. 147, 12–16 (2015).

Article  PubMed  Google Scholar 

Caicedo, E. Y. et al. Correction: The epidemiology of Mayaro virus in the Americas: A systematic review and key parameter estimates for outbreak modelling. PLoS Negl. Trop. Dis. 17, e0011034 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Larrieu, S. et al. Factors associated with persistence of arthralgia among Chikungunya virus-infected travellers: report of 42 French cases. J. Clin. Virol. 47, 85–88 (2010).

Article  PubMed  Google Scholar 

Borgherini, G. et al. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. Clin. Infect. Dis. 47, 469–475 (2008).

Article  PubMed  Google Scholar 

Soumahoro, M. K. et al. Impact of Chikungunya virus infection on health status and quality of life: a retrospective cohort study. PLoS One 4, e7800 (2009).

Article  ADS  PubMed  PubMed Central  Google Scholar 

Sissoko, D. et al. Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl. Trop. Dis. 3, e389 (2009).

Article  PubMed  PubMed Central  Google Scholar 

Couturier, E. et al. Impaired quality of life after chikungunya virus infection: a 2-year follow-up study. Rheumatol. (Oxf.) 51, 1315–1322 (2012).

Article  Google Scholar 

Soumahoro, M. K. et al. The Chikungunya epidemic on La Reunion Island in 2005-2006: a cost-of-illness study. PLoS Negl. Trop. Dis. 5, e1197 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Alvis-Zakzuk, N. J. et al. Economic Costs of Chikungunya Virus in Colombia. Value Health Reg. Issues 17, 32–37 (2018).

Article  PubMed  Google Scholar 

Staikowsky, F. et al. Retrospective survey of Chikungunya disease in Reunion Island hospital staff. Epidemiol. Infect. 136, 196–206 (2008).

Article  CAS  PubMed  Google Scholar 

Harrison, V. R., Eckels, K. H., Bartelloni, P. J. & Hampton, C. Production and Evaluation of a Formalin-Killed CHIKV vaccine. J. Immunol. 107, 643–647 (1971).

Article  CAS  PubMed  Google Scholar 

Metz, S. W. & Pijlman, G. P. Production of Chikungunya Virus-Like Particles and Subunit Vaccines in Insect Cells. Methods Mol. Biol. 1426, 297–309 (2016).

Article  CAS  PubMed  Google Scholar 

Khan, M., Dhanwani, R., Rao, P. V. & Parida, M. Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice. Virus Res. 167, 236–246 (2012).

Article  CAS  PubMed  Google Scholar 

Chang, L. J. et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 384, 2046–2052 (2014).

Article  CAS  PubMed  Google Scholar 

Chen, G. L. et al. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. JAMA 323, 1369–1377 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramsauer, K. et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect. Dis. 15, 519–527 (2015).

Article  CAS  PubMed  Google Scholar 

Folegatti, P. M. et al. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat. Commun. 12, 4636 (2021).

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat. Med. 27, 2224–2233 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Norrby, E. Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine. J. Exp. Med. 204, 2779–2784 (2007).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matrajt, L., Britton, T., Halloran, M. E. & Longini, I. M. Jr One versus two doses: What is the best use of vaccine in an influenza pandemic? Epidemics 13, 17–27 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Barnabas, R. V. & Wald, A. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose. Ann. Intern. Med. 174, 552–553 (2021).

Article  PubMed  Google Scholar 

Burger, E. A., Campos, N. G., Sy, S., Regan, C. & Kim, J. J. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. Vaccine 36, 4823–4829 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Levitt, N. H. et al. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 4, 157–162 (1986).

Article  CAS  PubMed  Google Scholar 

Gorchakov, R. et al. Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J. Virol. 86, 6084–6096 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ly H. Ixchiq (VLA1553): The first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection. Virulence. 15, 2301573 (2024)

Hallengard, D. et al. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J. Virol. 88, 2858–2866 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Roques, P. et al. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. JCI Insight 2, e83527 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Wressnigg, N. et al. Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. Lancet Infect. Dis. 20, 1193–1203 (2020).

Article  PubMed  Google Scholar 

Valneva. (ed Valneva Austria GmbH) (2021).

McMahon, R. et al. A randomized, double-blinded phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults. J. Travel Med. 13, taad156 (2023).

Google Scholar 

Weger-Lucarelli, J., Aliota, M. T., Kamlangdee, A. & Osorio, J. E. Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses. PLoS Negl. Trop. Dis. 9, e0004163 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Weger-Lucarelli, J. et al. Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity. J. Virol. 90, 2418–2433 (2015).

Article  PubMed  Google Scholar 

Capitini, C. M., Fry, T. J. & Mackall, C. L. Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer. Am. J. Immunol. 5, 65–83 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pennslyvania, U. o. PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection. (2016).

NIAID. Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without Different Booster Vaccinations in HIV Uninfected Adults. (2021).

Chen, T. et al. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. J. Immunother. Cancer 9, e001647 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Li, M. Safety of Recombinant Human IL-21 O